Bibliography
- Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002;50:585-8
- Iredale JP. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003;327:143-7
- Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-35
- Fallowfield JA, Iredale JP. Reversal of liver fibrosis and cirrhosis–an emerging reality. Scott Med J 2004;49:3-6
- Beljaars L, Molema G, Weert B, et al. Albumin modified with mannose 6-Phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999;29:1486-93
- Friedman SL. Liver fibrosis–from bench to bedside. J Hepatol 2003;38:S38-53
- Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18
- Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001;21:417-26
- Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397-416
- Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002;50:571-81
- Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005;42:S22-36
- Beljaars L, Poelstra K, Molema G, Meijer DKF. Targeting sugar- and charge-modified albumins to fibrotic rat livers: the accessibility of hepatic cells after chronic bile duct ligation. J Hepatol 1998;29:579-88
- Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11:S81-91
- Beljaars L, Meijer DK, Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002;7:e214-22
- Elrick LJ, Leel V, Blaylock MG, et al. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells – a potential mechanism for targeting liver anti-fibrotic therapeutics. J Hepatol 2005;42:888-96
- Beljaars L, Molema G, Schuppan D, et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 2000;275:12743-51
- Aina OH, Marik J, Liu R, et al. Identification of novel targeting peptides for human ovarian cancer cells using ‘one-bead one-compound’ combinatorial libraries. Mol Cancer Ther 2005;4:806-13
- De Bleser PJ, Scott CD, Niki T, et al. Insulin-like growth factor II/mannose 6-phosphate-receptor expression in liver and serum during acute CCl4 intoxication in the rat. Hepatology 1996;23:1530-7
- Scharf JG, Knittel T, Dombrowski F, et al. Characterization of the IGF axis components in isolated rat hepatic stellate cells. Hepatology 1998;27:1275-84
- Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 1992;61:307-30
- Beljaars L, Olinga P, Molema G, et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P28-HSA). Liver 2001;21:320-8
- Schneiderhan W, Schmid-Kotsas A, Zhao J, et al. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology 2001;34:729-37
- Adrian JE, Poelstra K, Scherphof GL, et al. Interaction of targeted liposomes with primary cultured hepatic stellate cells: involvement of multiple receptor systems. J Hepatol 2006;44:560-7
- Kamps JA, Morselt HW, Swart PJ, et al. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci USA 1997;94:11681-5
- Dahms NM, Hancock MK. P-type lectins. Biochim Biophys Acta 2002;1572:317-40
- Hughes DA, Fraser IP, Gordon S. Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. Eur J Immunol 1995;25:466-73
- Pitas RE, Friera A, McGuire J, Dejager S. Further characterization of the acetyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts. Arterioscler Thromb 1992;12:1235-44
- Schuppan D, Strobel D, Hahn EG. Hepatic fibrosis – therapeutic strategies. Digestion 1998;59:385-90
- Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev 1997;77:759-803
- Luk JM, Zhang QS, Lee NP, et al. Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. Liver Intern 2007;27:548-57
- Hagens WI, Beljaars L, Mann DA, et al. Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers. J Pharmacol Exp Ther 2008;324:902-10
- Gonzalo T, Talman EG, Van de Ven A, et al. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J Control Release 2006;111:193-203
- Gonzalo T, Bataller R, Sancho-Bru P, et al. Short-term treatment with losartan targeted to activated stellate cells reduces advanced liver fibrogenesis: a new strategy to treat liver fibrosis. Hepatology 2005;42:604A
- Greupink R, Bakker HI, Bouma W, et al. The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. J Pharmacol Exp Ther 2006;317:514-21
- Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-30
- Isaka Y, Tsujie M, Ando Y, et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 2000;58:1885-92
- Adrian JE, Kamps JA, Poelstra K, et al. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes. J Drug Target 2007;15:75-82
- Adrian JE, Poelstra K, Scherphof GL, et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats. J Pharmacol Exp Ther 2007;321:536-43
- Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715
- Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med 1998;76:253-65
- Loreal O, Clement B, Schuppan D, et al. Distribution and cellular origin of collagen VI during development and in cirrhosis. Gastroenterology 1992;102:980-7
- Takahara T, Sollberg S, Muona P, Uitto J. Type VI collagen gene expression in experimental liver fibrosis: quantitation and spatial distribution of mRNAs, and immunodetection of the protein. Liver 1995;15:78-86
- Marcelino J, McDevitt CA. Attachment of articular cartilage chondrocytes to the tissue form of type VI collagen. Biochim Biophys Acta 1995;1249:180-8
- Meijer DKF, Beljaars L, Molema G, Poelstra K. Disease-induced drug targeting using novel peptide-ligand albumins. J Control Release 2001;72:157-64
- Du SL, Pan H, Lu WY, et al. Cyclic Arg-Gly-Asp peptide labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007;322:560-8
- Li F, Sun JY, Wang JY, et al. Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. J Control Release 2008;131:77-82
- Edelmann L, Hanson PI, Chapman ER, Jahn R. Synaptobrevin binding to synaptophysin: a potential mechanism for controlling the exocytotic fusion machine. EMBO J 1995;14:224-31
- Kalina M, Lukinius A, Grimelius L, et al. Ultrastructural localization of synaptophysin to the secretory granules of normal glucagon and insulin cells in human islets of Langerhans. Ultrastruct Pathol 1991;15:215-9
- Gould VE, Lee I, Warren WH. Immunohistochemical evaluation of neuroendocrine cells and neoplasms of the lung. Pathol Res Pract 1988;183:200-13
- Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:453-63
- Poola I, Graziano SL. Expression of neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines. J Exp Clin Cancer Res 1998;17:165-73
- Evans GJ. Tyrosine phosphorylation of synaptophysin in synaptic vesicle recycling. Biochem Soc Trans 2005;33:1350-3
- Cassiman D, van Pelt J, De Vos R, et al. Synaptophysin: a novel marker for human and rat hepatic stellate cells. Am J Pathol 1999;155:1831-9
- Elrick LJ, Leel V, Blaylock MG, et al. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells – a potential mechanism for targeting liver anti-fibrotic therapeutics. J Hepatol 2005;42:888-96
- Douglass A, Wallace K, Parr R, et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 2008;49:88-98
- Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999;277:C1-9
- Heldin CH. Simultaneous induction of stimulatory and inhibitory signals by PDGF. FEBS Lett 1997;410:17-21
- Claesson-Welsh L. Signal transduction by the PDGF receptors. Prog Growth Factor Res 1994;5:37-54
- Friedman SL. The virtuosity of hepatic stellate cells. Gastroenterology 1999;117:1244-6
- Win KM, Charlotte F, Mallat A, et al. Mitogenic effect of transforming growth factor-beta 1 on human Ito cells in culture—evidence for mediation by endogenous platelet-derived growth factor. Hepatology 1993;18:137-45
- Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of β platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994;94:1563-9
- Pinzani M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996;148:785-800
- Clements JM, Bawden LJ, Bloxidge RE, et al. Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation. EMBO J 1991;10:4113-20
- Beljaars L, Weert B, Geerts A, et al. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol 2003;66:1307-17
- Fretto LJ, Snape AJ, Tominson JE, et al. Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta receptor. J Biol Chem 1993;268:3625-31
- Li L, Tao J, Davaille J, et al. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 2001;276:38152-8
- Li L, Grenard P, Nhieu JT, et al. Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 2003;125:460-9
- Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-22
- Cawello W, Schweer H, Muller R, et al. Metabolism and pharmacokinetics of prostaglandin E(1) administered by intravenous-infusion in human subjects. Eur J Clin Pharmacol 1994;46:275-7
- Hagens WI, Mattos A, Greupink R, et al. Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated. Pharm Res 2007;24:566-74
- Blomhoff R, Wake K. Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J 1991;5:271-7
- Fortuna VA, Martucci RB, Trugo LC, Borojevic R. Hepatic stellate cells uptake of retinol associated with retinol-binding protein or with bovine serum albumin. J Cell Biochem 2003;90:792-805
- Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat biotechnol 2008;26:431-42
- Sauk JJ, Smith T, Norris K, Ferreira L. Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(I) chains of type I procollagen. J Biol Chem 1994;269:3941-6
- Nagata K. Expression and function of heat shock protein 47: a collagen-specific molecular chaperone in the endoplasmic reticulum. Matrix Biol 1998;16:379-86
- Rockey DC. The cell and molecular biology of hepatic fibrogenesis: clinical and therapeutic implications. Clin Liver Dis 2000;4:319-55
- Fujimoto J, Kaneda Y. Reversing liver cirrhosis: impact of gene therapy for liver cirrhosis. Gene Ther 1999;6:305-6
- Monahan PE, Salmuski RJ. AAV vectors: is clinical success on the horizon? Gene Ther 2000;7:24-30
- Summerford C, Samulski RJ. Membrane-associated heparin sulfate proteoglycan is a receptor for adeno-associated virus type 2 virons. J Virol 1998;72:1438-45
- Summerford C, Bartlett J, Samulski RJ. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999;5:78-82
- Qing K, Mah C, Hansen J, et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adenoassociated virus 2. Nat Med 1999;5:71-7
- Tsui TY, Lau CK, Ma J, et al. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats. Hepatology 2005;42:335-42
- Bioulac-Sage P, Kuiper J, Van Berkel TJ, Balabaud C. Lymphocyte and macrophage populations in the liver. Hepatogastroenterology 1996;43:4-14
- Adams DH. Lymphocyte-endothelial cell interactions in hepatic inflammation. Hepatogastroenterology 1996;43:32-43
- Bijsterbosch MK, Manoharan M, Rump ET, et al. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 1997;25:3290-6
- Schnitzer JE, Bravo J. High affinity binding, endocytosis, and degradation of informationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors. J Biol Chem 1993;268:7562-70
- Yoshioka T, Yamamoto K, Kobashi H, et al. Receptor-mediated endocytosis of chemically modified albumins by sinusoidal endothelial cells and Kupffer cells in rat and human liver. Liver 1994;14:129-37
- De Rijke YB, Biessen EA, Vogelezang CJ, Van Berkel TJ. Binding characteristics of scavenger receptors on liver endothelial and Kupffer cells for modified low-density lipoproteins. Biochem J 1994;304:69-73
- Melgert BN, Wartna E, Lebbe C, et al. Targeting of naproxen covalently linked to HSA to sinusoidal cell types of the liver. J Drug Target 1998;5:329-42
- Kamps JA, Morselt HW, Swart PJ, et al. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci USA 1997;94:11681-5
- Jansen RW, Olinga P, Harms G, Meijer DK. Pharmacokinetic analysis and cellular distribution of the anti-HIV compound succinylated human serum albumin (Suc-HSA) in vivo and in the isolated perfused rat liver. Pharm Res 1993;10:1611-4
- Franssen EJ, Jansen RW, Vaalburg M, Meijer DK. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. Biochem Pharmacol 1993;45:1215-26
- Jansen RW, Molema G, Ching TL, et al. Hepatic endocytosis of various types of mannose-terminated albumins. What is important, sugar recognition, net charge or the combination of these features. J Biol Chem 1991;266:3343-8
- Beljaars L, Poelstra K, Molema G, Meijer DK. Targeting sugar- and charge-modified albumins to fibrotic rat livers: the accessibility of hepatic cells after chronic bile duct ligation. J Hepatol 1998;29:579-88
- Melgert BN, Olinga P, Jack VK, et al. Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cells. J Hepatol 2000;32:603-11
- Melgert BN, Weert B, Schellekens H, et al. The pharmacokinetic and biological activity profile of dexamethasone targeted to sinusoidal endothelial and kupffer cells. J Drug Target 2003;11:1-0
- Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65
- Friedman SL. Targeting siRNA to arrear fibrosis. Nat Biotechnol 2008;26:399-40
- Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50